A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis

This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Birch will be evaluated in a rush regimen (maximum dose reached in 3 injections during 3 weeks) compared to the conventional regimen (maximum dose reached in 6 injections during 6 weeks).
The primary endpoint of the sudy is the comparison of the proportions of the patients who have successfully reached the maintenance dose between the two treatment regimes.
A similar previous study with PURETHAL Grasses has shown that the rush up-dosing scheme is as safe as the conventional up-dosing regime. Therefore it is expected that up-dosing with PURETHAL Birch according to the rush regimen is as safe as using the conventional regimen.

开始日期2013-09-01

申办/合作机构

HAL Allergy Holding BV

[+1]

NCT01438463 / Completed临床2期

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis

The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
For this purpose 5 groups of 50 patients, suffering from rhinitis or rhinoconjunctivitis due to House Dust Mite Allergy will be treated during 1 year. Before start, after 6 months of treatment and at the end of the study patients will be subjected to a nasal provocation test.

开始日期2011-09-01

申办/合作机构

HAL Allergy Holding BV

EUCTR2011-000393-61-BE / Not yet recruiting临床2期

A multi-centre, randomized, double-blind, placebo-controlled, dose range finding study to identify the optimal (i.e. safe and effective) dose of PURETHAL® Mites SCIT in patients with house dust mites-induced persistent allergic rhinitis/rhinoconjunctivitis. - PURETHAL® Mites Dose Range Finding study in patients with persistent allergic rhinitis/rhinoconjunct

开始日期2011-08-05

申办/合作机构-

100 项与 House dust mite allergy vaccine(HAL Allergy Holding BV) 相关的临床结果

登录后查看更多信息

100 项与 House dust mite allergy vaccine(HAL Allergy Holding BV) 相关的转化医学

登录后查看更多信息

100 项与 House dust mite allergy vaccine(HAL Allergy Holding BV) 相关的专利（医药）

登录后查看更多信息

项与 House dust mite allergy vaccine(HAL Allergy Holding BV) 相关的文献（医药）

2014-01-01·International Archives of Allergy and Immunology3区 · 医学

Assessing the Efficacy of Immunotherapy with a Glutaraldehyde-Modified House Dust Mite Extract in Children by Monitoring Changes in Clinical Parameters and Inflammatory Markers in Exhaled Breath

3区 · 医学

Article

作者: Cruz, Maria-Jesus ; Piquer, Monica ; Lozano, Jaime ; Giner, Maria-Teresa ; Plaza, Ana Maria

INTRODUCTIONThe aim of this study was to evaluate the effectiveness of specific immunotherapy (SIT) management with allergoids in children with allergic asthma by monitoring changes in clinical parameters and inflammatory markers in exhaled breath.METHODSThe study population included 43 patients (24 males) of 6-14 years of age, who had allergic asthma and were sensitized to mites. Twenty-three individuals were treated with subcutaneous SIT (PURETHAL® Mites, HAL Allergy) for 8 months, i.e. the SIT group, and 20 were given medication to treat symptoms only, i.e. the control group. Before treatment and after 4 and 8 months, several clinical parameters, the levels of exhaled nitric oxide and the pH of exhaled breath condensate (EBC) were determined.RESULTSThe SIT group presented with an improvement in asthma classification, a reduction in maintenance drug therapy and improved scores on the quality-of-life questionnaire. These changes were not observed in the control group. Both groups presented significant decreases in EBC pH values at 4 and 8 months after treatment compared to at baseline. However, analysis of the variable 'ratio' showed an increase in the EBC pH values after 8 months of treatment in the SIT group compared with the values at 4 months.CONCLUSIONSSIT with standardized mite extract reduces asthma symptoms in children. A decrease in EBC pH values was observed in both groups, although the SIT group presented a tendency of recovered values after 8 months. Future studies of EBC pH monitoring in the longer term are needed to determine the effectiveness of this marker.

100 项与 House dust mite allergy vaccine(HAL Allergy Holding BV) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V01AA03	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
变应性结膜炎	德国	HAL Allergy Holding BV	2011-01-01
过敏性鼻炎	德国	HAL Allergy Holding BV	2011-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
屋尘螨过敏	临床前	西班牙	HAL Allergy Holding BV	2011-09-01
屋尘螨过敏	临床前	荷兰	HAL Allergy Holding BV	2011-09-01
屋尘螨过敏	临床前	德国	HAL Allergy Holding BV	2011-09-01
屋尘螨过敏	临床前	奥地利	HAL Allergy Holding BV	2011-09-01
屋尘螨过敏	临床前	比利时	HAL Allergy Holding BV	2011-09-01
鼻结膜炎	临床前	德国	HAL Allergy Holding BV	2011-09-01
鼻结膜炎	临床前	奥地利	HAL Allergy Holding BV	2011-09-01
鼻结膜炎	临床前	比利时	HAL Allergy Holding BV	2011-09-01
鼻结膜炎	临床前	荷兰	HAL Allergy Holding BV	2011-09-01
鼻结膜炎	临床前	西班牙	HAL Allergy Holding BV	2011-09-01